↓ Skip to main content

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Overview of attention for article published in New England Journal of Medicine, June 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Citations

dimensions_citation
3162 Dimensions

Readers on

mendeley
1372 Mendeley
citeulike
6 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Published in
New England Journal of Medicine, June 2009
DOI 10.1056/nejmoa0900212
Pubmed ID
Authors

Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor, Alan Ashworth, James Carmichael, Stan B Kaye, Jan H M Schellens, Johann S de Bono

Abstract

The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1,372 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 10 <1%
United Kingdom 5 <1%
Spain 3 <1%
Belgium 3 <1%
Germany 2 <1%
Australia 2 <1%
Sweden 2 <1%
Canada 2 <1%
India 1 <1%
Other 10 <1%
Unknown 1332 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 264 19%
Researcher 204 15%
Student > Bachelor 165 12%
Student > Master 152 11%
Other 73 5%
Other 226 16%
Unknown 288 21%
Readers by discipline Count As %
Medicine and Dentistry 330 24%
Biochemistry, Genetics and Molecular Biology 299 22%
Agricultural and Biological Sciences 252 18%
Pharmacology, Toxicology and Pharmaceutical Science 40 3%
Chemistry 31 2%
Other 91 7%
Unknown 329 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 41. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2023.
All research outputs
#999,366
of 25,374,647 outputs
Outputs from New England Journal of Medicine
#9,627
of 32,472 outputs
Outputs of similar age
#2,676
of 123,469 outputs
Outputs of similar age from New England Journal of Medicine
#28
of 180 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,472 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 122.0. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 123,469 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 180 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.